Free RAC Regulatory Submissions and Approval Questions and Answers 1 — Questions and Answers
Question 1: A pharmaceutical company is preparing a marketing application for a new chemical entity to be submitted in the US, EU, and Japan. Which document provides a harmonized structure for the quality, nonclinical, and clinical sections of the application, thereby streamlining the submission process across these regions?
- Investigational New Drug (IND) Application
- Common Technical Document (CTD) (Correct answer)
- Biologics License Application (BLA)
- New Drug Application (NDA)
Correct answer: Common Technical Document (CTD)
The Common Technical Document (CTD), developed by the International Council for Harmonisation (ICH), provides a standardized format for regulatory submissions in the ICH regions (US, EU, Japan). It is organized into five modules, with Modules 2 through 5 being common across regions, which significantly reduces the effort needed to compile applications for different regulatory authorities.
Question 2: A medical device company is preparing a premarket submission for a new Class II diagnostic device. The device has the same intended use and similar technological characteristics as a legally marketed device (a predicate device). Which type of submission is MOST appropriate to seek marketing authorization in the United States?
- Premarket Approval (PMA)
- Investigational Device Exemption (IDE)
- De Novo Classification Request
- Premarket Notification (510(k)) (Correct answer)
Correct answer: Premarket Notification (510(k))
A Premarket Notification (510(k)) is the appropriate submission pathway for a device that is substantially equivalent to a legally marketed predicate device. This pathway is used for most Class II devices and some Class I devices. The submission's purpose is to demonstrate that the new device is as safe and effective as the predicate.
Question 3: A sponsor of an approved Class III medical device is required to submit post-approval reports to the FDA to ensure continued safety and effectiveness. Which of the following is a mandatory reporting requirement for the holder of an approved Premarket Approval (PMA) application?
- Submitting a 510(k) for any manufacturing change.
- Quarterly reports on sales and distribution data.
- Periodic Medical Device Reports (MDRs) for adverse events and annual reports. (Correct answer)
- A De Novo petition to confirm the device classification.
Correct answer: Periodic Medical Device Reports (MDRs) for adverse events and annual reports.
Holders of an approved PMA are subject to post-approval requirements, which include submitting Medical Device Reports (MDRs) for deaths, serious injuries, and certain malfunctions as per 21 CFR 803. They are also typically required to submit annual reports summarizing new safety and effectiveness information.
Question 4: A pharmaceutical sponsor has an active Investigational New Drug (IND) application for a product in Phase 2 clinical trials. According to FDA regulations (21 CFR 312.33), what must the sponsor submit to the FDA within 60 days of the anniversary date of the IND going into effect?
- A New Drug Application (NDA)
- A complete Development Safety Update Report (DSUR)
- An IND Annual Report (Correct answer)
- A 15-day Alert Report
Correct answer: An IND Annual Report
Under 21 CFR 312.33, sponsors are required to submit an IND Annual Report to the FDA. This report must be submitted within 60 days of the anniversary of the date the IND went into effect and should summarize the status of ongoing studies, provide a summary of the previous year's findings, and update any new information.
Question 5: When preparing the technical documentation for a medical device to be marketed in the European Union under the Medical Device Regulation (MDR - EU 2017/745), which of the following is a critical component required in Annex II?
- A copy of the company's annual financial report.
- A summary of all marketing and sales activities.
- A detailed description of the design and manufacturing processes. (Correct answer)
- The curriculum vitae of the company's Chief Executive Officer.
Correct answer: A detailed description of the design and manufacturing processes.
Annex II of the EU MDR outlines the required contents of the technical documentation. A key element is detailed information concerning the design and manufacture of the device. This includes drawings, specifications, and a description of the manufacturing methods and facilities to demonstrate conformity with the General Safety and Performance Requirements.
Question 6: A company receives approval for a New Drug Application (NDA). Several years post-approval, the FDA requires the sponsor to conduct a new clinical trial to assess a newly identified serious risk associated with the drug's long-term use. This type of study is BEST described as a:
- Phase 4 Clinical Trial
- Postmarket Requirement (PMR) (Correct answer)
- Investigator-Initiated Study
- Post-Approval Commitment (PMC)
Correct answer: Postmarket Requirement (PMR)
A study that FDA requires a sponsor to conduct after a drug is approved is called a Postmarket Requirement (PMR). The Food and Drug Administration Amendments Act (FDAAA) of 2007 gave the FDA authority to require PMRs to assess known serious risks, signals of serious risk, or to identify unexpected serious risks. A Post-Approval Commitment (PMC) is a study the sponsor agrees to conduct but is not strictly required by law.
Free RAC Regulatory Submissions and Approval Questions and Answers 1
A pharmaceutical company is preparing a marketing application for a new chemical entity to be submitted in the US, EU, and Japan.
Which document provides a harmonized structure for the quality, nonclinical, and clinical sections of the application, thereby streamlining the submission process across these regions?